Study description
A prospective, observational, monocentric study to measure compliance with the use of Cureety in patients with prostate cancer.
Key results
High remote monitoring compliance of 72% during the first month, 59% at 8 monthsPatients divided in 2 groups based on the 1st month of monitoring: 'Healthy' (87%) and 'Poor Health' (13%) 29% increase of progression-free survival at 6 months in the 'Healthy' group (p=0.17) 14% increase of overall survival at 6 months in the 'Healthy' group (p=0.15)
Publication
Helissey et al., 2023, Front. Digit. Health
